Decentralised clinical trial (DCT) technology and consulting service provider Thread has acquired US-based CureClick to improve the pathway from clinical trial awareness to access.
Established in 2013, CureClick provides the world’s first crowdsourcing platform built to expedite clinical research awareness and participation.
Its existing community-steered network comprises over 6,500 ambassadors and patient advocates representing more than 75 disease states with a global reach exceeding one million patients.
With the acquisition, CureClick founder Fabio Gratton will take over as Thread’s chief experience officer.
Furthermore, CureClick’s technology and a wide network of community leaders will become part of the global patient enrolment offering of Thread.
This new scaled marketplace will function as Thread’s DCT platform feature, further automating and simplifying the pathway from trial education to enrolment for DCTs worldwide.
The latest deal comes after Thread’s recent acquisition of Modus Outcomes and inVibe.
Thread CEO John Reites said: “One of the advantages of decentralisation is engaging patients from broader geographic areas and more diverse backgrounds into clinical research so that trials better represent real-world populations.
“CureClick helps our customers make their clinical trials more accessible and inclusive while better supporting our existing base of premier recruitment-focused partners who can leverage a new marketplace for their services.”
Thread aids biopharma and contract research organisations in decentralising clinical research and facilitating electronic clinical outcome assessments for subjects, sites, caregivers and home health specialists.
In February this year, Thread and life sciences commercial services company Eversana partnered to provide a new decentralised registry and real-world data (RWD)-driven solution for pharmaceutical firms.